Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy
In this study, HER2 RNA aptamers were conjugated to mertansine (DM1) and the anti-cancer effectiveness of the conjugate was evaluated in HER2-overexpressing breast cancer models. The conjugate of HER2 aptamer and anticancer drug DM1 (aptamer-drug conjugate, ApDC) was prepared and analyzed using HPLC...
Main Authors: | Hwa Yeon Jeong, Hyeri Kim, Myunghwa Lee, Jinju Hong, Joo Han Lee, Jeonghyeon Kim, Moon Jung Choi, Yong Serk Park, Sung-Chun Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/24/9764 |
Similar Items
-
Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents
by: Prabir Kumar Kulabhusan, et al.
Published: (2020-07-01) -
Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer
by: Xiaolin Yu, et al.
Published: (2018-03-01) -
Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer
by: Marlies Gijs, et al.
Published: (2016-05-01) -
Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents
by: Minhee Kim, et al.
Published: (2018-04-01) -
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive <it>Breast</it> Cancer Cells <it>in Vitro</it>
by: Liu Zhe, et al.
Published: (2012-07-01)